99 related articles for article (PubMed ID: 17998668)
1. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma.
Rakesh Kumar V; Gupta N; Kakkar N; Sharma SC
J Cancer Res Ther; 2006; 2(1):20-3. PubMed ID: 17998668
[TBL] [Abstract][Full Text] [Related]
2. Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies.
Liu Y; Ma YH; Sun ZZ; Rui YJ; Yin QD; Song S; Wei XM; Liu J; Liu XG; Hu KJ
Tumour Biol; 2014 Sep; 35(9):8939-43. PubMed ID: 24899264
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
4. C-erbB-2 expression and prognostic significance in osteosarcoma.
Yalçin B; Gedikoğlu G; Kutluk T; Varan A; Akyüz C; Büyükpamukçu M
Pediatr Blood Cancer; 2008 Aug; 51(2):222-7. PubMed ID: 18421709
[TBL] [Abstract][Full Text] [Related]
5. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann JS; Baker L
Clin Cancer Res; 2002 Mar; 8(3):788-93. PubMed ID: 11895910
[TBL] [Abstract][Full Text] [Related]
6. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.
Gorlick S; Barkauskas DA; Krailo M; Piperdi S; Sowers R; Gill J; Geller D; Randall RL; Janeway K; Schwartz C; Grier H; Meyers PA; Gorlick R; Bernstein M; Marina N
Pediatr Blood Cancer; 2014 Sep; 61(9):1558-64. PubMed ID: 24753182
[TBL] [Abstract][Full Text] [Related]
7. Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
Gorlick R; Huvos AG; Heller G; Aledo A; Beardsley GP; Healey JH; Meyers PA
J Clin Oncol; 1999 Sep; 17(9):2781-8. PubMed ID: 10561353
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Role of Ezrin and HER2/neu Expression in Osteosarcoma.
Abdou AG; Kandil M; Asaad NY; Dawoud MM; Shahin AA; Abd Eldayem AF
Appl Immunohistochem Mol Morphol; 2016; 24(5):355-63. PubMed ID: 26067138
[TBL] [Abstract][Full Text] [Related]
9. XB130 expression in human osteosarcoma: a clinical and experimental study.
Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma.
Morris CD; Gorlick R; Huvos G; Heller G; Meyers PA; Healey JH
Clin Orthop Relat Res; 2001 Jan; (382):59-65. PubMed ID: 11154005
[TBL] [Abstract][Full Text] [Related]
11. Her-2/neu, p-53, and their coexpression in osteosarcoma.
Bakhshi S; Gupta A; Sharma MC; Khan SA; Rastogi S
J Pediatr Hematol Oncol; 2009 Apr; 31(4):245-51. PubMed ID: 19346874
[TBL] [Abstract][Full Text] [Related]
12. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
13. ErbB2 expression is correlated with increased survival of patients with osteosarcoma.
Akatsuka T; Wada T; Kokai Y; Kawaguchi S; Isu K; Yamashiro K; Yamashita T; Sawada N; Yamawaki S; Ishii S
Cancer; 2002 Mar; 94(5):1397-404. PubMed ID: 11920494
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
15. Question about Liu Y et al. entitled "Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies".
Yin X; Deng F; Liao G
Tumour Biol; 2015 Sep; 36(9):6667-8. PubMed ID: 26242268
[TBL] [Abstract][Full Text] [Related]
16. Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma.
Aznab M; Khajevand Ahmady M; Jamshidi K; Madani SH; Khazaei S; Shoushtaryzadeh T; Bagheri A
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3005-3009. PubMed ID: 33112560
[TBL] [Abstract][Full Text] [Related]
17. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.
Abdeen A; Chou AJ; Healey JH; Khanna C; Osborne TS; Hewitt SM; Kim M; Wang D; Moody K; Gorlick R
Cancer; 2009 Nov; 115(22):5243-50. PubMed ID: 19670450
[TBL] [Abstract][Full Text] [Related]
18. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.
Boulytcheva IV; Soloviev YN; Kushlinskii NE; Mahson AN
Bull Exp Biol Med; 2010 Dec; 150(2):237-42. PubMed ID: 21240382
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis.
Cates JM; Friedman DB; Seeley EH; Dupont WD; Schwartz HS; Holt GE; Caprioli RM; Young PP
Int J Exp Pathol; 2010 Aug; 91(4):335-49. PubMed ID: 20353421
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma.
Li YG; Geng X
Eur J Cancer Care (Engl); 2010 May; 19(3):313-6. PubMed ID: 19709164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
